Efficacy of conventional immunosuppressive drugs in IBD.
The introduction and rapid diffusion of biological agents in the treatment of inflammatory bowel disease had led us to believe that the old immunosuppressive drugs were destined to disappear. However, despite a decade of clinical experience in the use of biological agents, the old immunosuppressive drugs continue to play a pivotal role in the management of inflammatory bowel disease. Various factors may account for this change of view. Aim of the present review was to summarise key information currently available regarding the use of immunosuppressive drugs in the treatment of inflammatory bowel disease.
Caprilli
R
R
GI Unit, Department of Clinical Science, University of Rome La Sapienza, Viale del Policlinico 155, 00161 Rome, Italy. renzo.caprilli@uniroma1.it
Angelucci
E
E
Cocco
A
A
Viscido
A
A
Zippi
M
M
D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D013792:Thalidomide; D016572:Cyclosporine; D015122:Mercaptopurine; D009173:Mycophenolic Acid; D001379:Azathioprine; D016559:Tacrolimus; D008727:Methotrexate